HHS Secretary Azar Likely To Advance Medicare Drug Pricing Policies

Alex Azar's nomination clears Senate with support from five Democrats and one Independent – but not Rand Paul, R-Ky.

Alex Azar, Trump’s HHS secretary nominee, who spoke at the Senate HELP committee 11/29/17
Alex Azar testifies at his confirmation hearing before the Senate HELP Committee on Nov. 29, 2017.

Now that his nomination to be HHS secretary has cleared the full Senate, Alex Azar is likely to focus on advancing the government's development of policies to reduce drug prices in Medicare Part D and Part B.

Azar's nomination was approved by the Senate in a 55-43 vote, with support from five Democrats and one Independent. (See...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Pricing Debate

Part B Negotiation Proposal Would Lower Prices In MA, Private Plans Too, Stakeholders Complain

 
• By 

The issue is attracting more attention as the 2028 deadline for implementing Medicare negotiated prices for Part B drugs approaches.

Here At Last: Canada’s Long-Contested Guidelines For Curbing Excessive Drug Prices

 

Final guidelines explaining how staff at Canada’s Patented Medicine Prices Review Board should go about identifying drugs that could be considered for an excessive price hearing will come into force soon.

Kennedy Appears Ill-Informed On Major Pharma Priorities, Creating Unique Lobbying Dynamics

 

The Health and Human Services Secretary made incorrect statements about the status of key industry priorities at a recent House hearing, which actually may be a good thing for drug sponsors.

US Budget Bill Eases IRA Price Controls But Coverage Losses Will Impact Pharma

 
• By 

The legislation expected to be signed by President Trump is a mixed bag for pharmaceutical manufacturers depending on their product mix and manufacturing situation.

More from Market Access